FOLH1 and posterior cortical atrophy: At National Centre for Nuclear Research, Radioisotope Center POLATOM a novel PSMA ligand, PSMA-T4 (Glu-CO-Lys-L-Trp-4-Amc-HYNIC) (molecular weight (MW) 779.36 g mol−1) was developed, which after radiolabeling with 99mTc potentially can be used in the diagnosis of PCa patients (patents pending: EP3721907A1; PL429630A1; US2020324000A1) [28].